contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


magnasense-interim-report-april-june-2024

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Subgen AI develops both infrastructure and proprietary agent-centric AI-as-a-Service software, branded Serenity Star. The company's solutions are designed to scale and accelerate the implementation of AI in organizations. Subgen AI delivers services to clients in sectors such as healthcare, energy, legal and human resources. Subgen AI operates in Europe, Latin America and the United States.

Subgen AI

"As we conclude the second quarter of 2024, I am pleased to share with you several key developments that position Magnasense AB for continued growth and success in the evolving healthcare diagnostics...

<div class="mfn-preamble">"As we conclude the second quarter of 2024, I am pleased to share with you several key developments that position Magnasense AB for continued growth and success in the evolving healthcare diagnostics sector," said Marco Witteveen, CEO of Magnasense.</div><div class="mfn-body">April-June• Total income amounted to 3,1 (1,3) MSEK. • Loss before tax amounted to -8,4 (-16,4) MSEK. • Cash and cash equivalents at the end of the quarter was 2,4 (36,6) MSEK. • Earnings per share* -0,26 (-0,61) SEK. • Equity ratio** at 30 June 2024 was -24 (31) %.Significant events during the period April-June• Jens Umehag joined Magnasense AB as the new Chairman of the Board, succeeding Anders Ingvarsson. •Michael Schwartz and William Ferenczy joined the Board as new members. • The terms and conditions of series 2023/2025 convertible loan notes, issued by Atlas Special Opportunities, were amended to extend the term and adjust conversion requirements. • Further funding has been agreed through an additional 36 month secured MSEK 45 loan facility with Atlas Special Opportunities. • Magnasense AB successfully completed an additional milestone in its participation in the NIH RADx Tech Program. • The Company published a study in Multiple Sclerosis and Related Disorders journal.Significant events after the end of the period• Aegirbio AB changed its name to Magnasense AB, to better reflect core assets and focus. • Melissa Grant, Associate Professor at the University of Birmingham’s School of Dentistry, joined Magnasense’s Scientific Advisory Board. • Vicki Johnson joined Magnasense AB as interim CFO, succeeding Christel Dahlberg.* Earnings per share: Profit for the period divided by the weighted average number of shares, which as of 2024-06-30 amounted to 31,758,392 shares before dilution. The corresponding number for the same period in the previous year was 23,913,424 shares. ** Equity ratio: Equity divided by total capital.</div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar">This information is information that Magnasense is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-23 08:00 CEST.</div><div class="mfn-footer mfn-contacts mfn-e503b60338ed">For additional information, please contact: Marco Witteveen, CEO, Magnasense AB Email: <a rel="noopener" href="mailto:ir@aegirbio.com">ir@magnasense.com</a> The Company’s Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se</div><div class="mfn-footer mfn-about mfn-8c31e8f3e677">About Magnasense AB Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/131b3635-678c-417d-ac8d-207838b9043e/magnasense-q2-2024-final-en.pdf" class="mfn-primary">Magnasense Q2 2024 Final (EN)</a></div>